Lexeo Therapeutics (LXEO) News Today $3.94 -0.15 (-3.67%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.93 -0.01 (-0.23%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Lexeo Therapeutics files to sell 41.63M shares of common stock for holdersJune 13 at 7:43 PM | msn.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLCMillennium Management LLC raised its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 282.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 141,951 shares of the company's stock after acquiringJune 6, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. dropped their target price on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating for the company in a report on Friday.May 31, 2025 | marketbeat.comLeerink Partnrs Issues Positive Forecast for LXEO EarningsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of (May 31, 2025 | marketbeat.comLexeo Therapeutics Announces $80 Mln Private Placement Of SharesMay 29, 2025 | nasdaq.comLexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular DiseasesMay 27, 2025 | globenewswire.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recomMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Trims Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Frazier Life Sciences Management L.P. reduced its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 23.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 955,515 shares of the company'May 23, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 102.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 750,235 shares of the company'sMay 22, 2025 | marketbeat.comVestal Point Capital LP Raises Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Vestal Point Capital LP grew its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 41.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,200,000 shares of the company's stock afMay 21, 2025 | marketbeat.comQ1 Earnings Forecast for LXEO Issued By HC WainwrightLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - HC Wainwright issued their Q1 2026 EPS estimates for Lexeo Therapeutics in a report issued on Friday, May 16th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.62) for the quarter. HC Wainwright hMay 21, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Lifted by Janus Henderson Group PLCJanus Henderson Group PLC raised its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 15.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,339,254 shares of the companyMay 17, 2025 | marketbeat.comLexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy RatingMay 16, 2025 | tipranks.comChardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock PriceChardan Capital cut their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research report on Tuesday.May 15, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLCOmega Fund Management LLC lessened its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 49.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,184,636 shares of the company's stock after selling 1,171,268 shares durMay 15, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPSLexeo Therapeutics (NASDAQ:LXEO - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19).May 14, 2025 | marketbeat.comLexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12, 2025 | globenewswire.comDAFNA Capital Management LLC Purchases 142,500 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)DAFNA Capital Management LLC increased its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 56.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 393,083 shares of the company's stock after purchasing an additional 142,500 shaMay 10, 2025 | marketbeat.comLexeo: Alignment Gained With FDA Brings Further LX2006 Program AdvancementMay 5, 2025 | seekingalpha.comLexeo Therapeutics (LXEO) Projected to Post Earnings on ThursdayLexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-lexeo-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comLexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingMay 1, 2025 | globenewswire.comAdage Capital Partners GP L.L.C. Sells 388,121 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Adage Capital Partners GP L.L.C. trimmed its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 14.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,209,615 shares of tApril 29, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy raApril 28, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by D1 Capital Partners L.P.D1 Capital Partners L.P. trimmed its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 12.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,203,900 shares of the company's stock after selling 302,7April 26, 2025 | marketbeat.comAltium Capital Management LLC Takes $2.67 Million Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Altium Capital Management LLC acquired a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 405,000 shares of the company's stock, valued at approApril 20, 2025 | marketbeat.comWhat is Chardan Capital's Estimate for LXEO FY2025 Earnings?Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at Chardan Capital boosted their FY2025 EPS estimates for shares of Lexeo Therapeutics in a research report issued on Tuesday, April 8th. Chardan Capital analyst G. Livshits now expects that the company will post earnings of ($April 13, 2025 | marketbeat.comChardan Capital Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $22.00Chardan Capital dropped their price objective on Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Tuesday.April 10, 2025 | marketbeat.comLexeo Therapeutics' (LXEO) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday.April 10, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)ADAR1 Capital Management LLC lifted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 196.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 169,505 shares of the company'sApril 9, 2025 | marketbeat.comLexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006April 8, 2025 | markets.businessinsider.comLexeo Therapeutics price target lowered to $22 from $25 at ChardanApril 8, 2025 | markets.businessinsider.comPromising Developments in Lexeo Therapeutics’ Gene Therapy Trials Support Buy RatingApril 8, 2025 | tipranks.comGene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In TrialsApril 7, 2025 | benzinga.comLexeo Therapeutics Reports Positive Interim Trial ResultsApril 7, 2025 | tipranks.comLexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational StudyApril 7, 2025 | globenewswire.comWhat is Chardan Capital's Forecast for LXEO FY2025 Earnings?Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a report released on Tuesday, March 25th. Chardan Capital analyst G. Livshits now anticipates that the company will posMarch 29, 2025 | marketbeat.comQ1 EPS Forecast for Lexeo Therapeutics Lifted by AnalystLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of Lexeo Therapeutics in a research report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.78) pMarch 29, 2025 | marketbeat.comFY2025 Earnings Estimate for LXEO Issued By Leerink PartnrsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research report issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company wiMarch 28, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)HC Wainwright reissued a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday.March 27, 2025 | marketbeat.comQ1 Earnings Forecast for LXEO Issued By Leerink PartnrsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.80) per share for thMarch 27, 2025 | marketbeat.comRoyal Bank of Canada Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $20.00Royal Bank of Canada lowered their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday.March 26, 2025 | marketbeat.comLexeo Therapeutics' (LXEO) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday.March 26, 2025 | marketbeat.comLexeo Therapeutics price target lowered to $18 from $19 at LeerinkMarch 26, 2025 | markets.businessinsider.comLexeo Therapeutics price target lowered to $20 from $24 at RBC CapitalMarch 26, 2025 | markets.businessinsider.comLexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPSLexeo Therapeutics (NASDAQ:LXEO - Get Free Report) announced its earnings results on Monday. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.March 25, 2025 | marketbeat.comLeerink Partners Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $18.00Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday.March 25, 2025 | marketbeat.comPharma Frenzy: Volatility Ignites Biotech SectorTwo biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.March 25, 2025 | marketbeat.comLexeo Therapeutics reports Q4 EPS (78c), consensus (78c)March 25, 2025 | markets.businessinsider.comLexeo Therapeutics sees cash runway into 2027March 25, 2025 | markets.businessinsider.comLexeo Therapeutics Advances Genetic Medicine InitiativesMarch 25, 2025 | tipranks.com Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼1.230.90▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼22▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News Today Relay Therapeutics News Today Keros Therapeutics News Today Arvinas News Today Maze Therapeutics News Today Tyra Biosciences News Today Verve Therapeutics News Today Opthea News Today Cullinan Therapeutics News Today Valneva News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
